Kardigan, Inc.
Research Kardigan, Inc. (KARD) on Bullrun: market cap USD 1.34B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKARD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.34B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 116.24M
- Free cash flow-USD 52.82M
Valuation Snapshot
latest market cap is USD 1.34B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 191.94M | -USD 157.70M | n/a | -3.2 | USD 108.99M | USD 13.83M | -USD 250.34M |
| FY2024 | USD 0 | -USD 88.66M | -USD 55.24M | n/a | -1.42 | USD 49.40M | USD 9.54M | -USD 83.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 1.34B | n/a | n/a | n/a |
About Kardigan, Inc.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kardigan, Inc.'s market cap?
Kardigan, Inc.'s market capitalization is USD 1.34B.
What does Kardigan, Inc. do?
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking.